Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

被引：0
|
作者：
John K. Botson
Katie Obermeyer
Brian LaMoreaux
Lin Zhao
Michael E. Weinblatt
Jeff Peterson
机构：
[1] Orthopedic Physicians Alaska,Division of Rheumatology, Immunology and Immunity
[2] Horizon Therapeutics plc,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Western Washington Arthritis Clinic,undefined
来源：
Arthritis Research & Therapy | / 24卷
关键词：
Pegloticase; Uncontrolled gout; Refractory gout; Immunomodulation; Methotrexate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 15 条
  • [11] ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT
    Peyrin-Biroulet, Laurent
    Rubin, David T.
    Feagan, Brian
    Oh, Young S.
    Arulmani, Udayasankar
    Tyrrell, Helen
    Maciuca, Romeo
    Williams, Sarah
    Tole, Swati
    Thommes, James
    GASTROENTEROLOGY, 2018, 154 (01) : S17 - S18
  • [12] ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT
    Peyrin-Biroulet, Laurent
    Rubin, David T.
    Feagan, Brian
    Oh, Young S.
    Arulmani, Udayasankar
    Tyrrell, Helen
    Maciuca, Romeo
    Williams, Sarah
    Tole, Swati
    Thommes, James
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S12 - S12
  • [13] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
  • [14] Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT-BC trial
    Kawahara, Takuya
    Shimozuma, Kojiro
    Shiroiwa, Takeru
    Hagiwara, Yasuhiro
    Uemura, Yukari
    Watanabe, Takanori
    Fukuda, Takashi
    Ohashi, Yasuo
    Mukai, Hirofumi
    QUALITY OF LIFE RESEARCH, 2016, 25 : 116 - 116
  • [15] Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Delforge, Michel
    Patel, Krina
    Eliason, Laurie
    Dhanda, Devender
    Shi, Ling
    Guo, Shien
    Marshall, Thomas S.
    Arnulf, Bertrand
    Cavo, Michele
    Nooka, Ajay
    Manier, Salomon
    Callander, Natalie
    Giralt, Sergio
    Einsele, Hermann
    Ailawadhi, Sikander
    Mckiver, Mihaela Popa
    Cook, Mark
    Rodriguez-Otero, Paula
    LANCET HAEMATOLOGY, 2024, 11 (03): : e216 - e227
12